[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 66 of about 66
1. Cilloni D, Messa F, Arruga F, Defilippi I, Gottardi E, Fava M, Carturan S, Catalano R, Bracco E, Messa E, Nicoli P, Diverio D, Sanz MA, Martinelli G, Lo-Coco F, Saglio G: Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica; 2008 Jun;93(6):921-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy.
  • The Wilms' tumor gene WT1 is a reliable marker for minimal residual disease assessment in acute leukemia patients.
  • The study was designed to demonstrate the potential use of WT1 to establish quality of remission in acute leukemia patients for early identification of patients at high risk of relapse.
  • A prospective study based on a quantitative Real-Time PCR (TaqMan) assay in 562 peripheral blood samples collected from 82 acute leukemia patients at diagnosis and during follow-up was established.
  • The evaluation of WT1 in peripheral blood samples after induction chemotherapy can distinguish the continuous complete remission patients from those who obtain only an "apparent" complete remission and who could relapse within a few months.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gene Expression Regulation, Neoplastic. Genes, Wilms Tumor. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / therapy. WT1 Proteins / blood

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443273.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; 0 / WT1 Proteins
  •  go-up   go-down


2. Kahng J, Shin SY, Han K: [Proportions of cells expressing CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, or CD13,33+/CD34+ in the regenerating bone marrows during complete remission of acute leukemia or after bone marrow transplantation]. Korean J Lab Med; 2007 Dec;27(6):406-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Proportions of cells expressing CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, or CD13,33+/CD34+ in the regenerating bone marrows during complete remission of acute leukemia or after bone marrow transplantation].
  • We attempted to discover the proportions of undifferentiated stem cells, committed stem cells, B cell precursors, and myeloid precursors in the regenerating bone marrows during complete remission (CR) and after engraftment of BMT.
  • METHODS: Bone marrow samples from 82 patients with acute leukemia in CR and from 25 patients after BMT engraftment, along with 22 control samples, were used to find the numbers of CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, and CD13,33+/CD34+ cells in the large lymphocyte gate by flow cytometry.
  • We cross-analyzed our results in terms of groups: CR, BMT, and initial diagnosis groups.
  • RESULTS: The proportions of CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, and CD13,33+/CD34+ cells are more highly distributed in acute B-lymphoblastic leukemia than the normal group and also in the CR than the BMT group.
  • [MeSH-major] Antigens, CD19 / metabolism. Antigens, CD34 / metabolism. Antigens, CD38 / metabolism. Bone Marrow Transplantation. Leukemia / metabolism
  • [MeSH-minor] Acute Disease. Bone Marrow / physiology. Flow Cytometry. Follow-Up Studies. Granulocyte Colony-Stimulating Factor / therapeutic use. Hematopoietic Stem Cells / immunology. Hematopoietic Stem Cells / metabolism. Humans. Immunophenotyping. Regeneration. Remission Induction

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18160830.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD34; 143011-72-7 / Granulocyte Colony-Stimulating Factor; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


3. Baz R, Rodriguez C, Fu AZ, Jawde RA, Kalaycio M, Advani A, Sobecks R, Sekeres MA: Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia. Cancer; 2007 Oct 15;110(8):1752-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia.
  • BACKGROUND: Significant controversy surrounds the use of remission induction chemotherapy (IC) in older adults with acute myeloid leukemia (AML).
  • After further adjusting for age, gender, race, leukocyte count at presentation, AML cytogenetics, history of prior hematologic disorder, and assessing for comorbidities, not receiving IC was still associated with worse survival (hazards ratio of 1.88; 95% confidence interval, 1.15-3.05 [P = .01]).
  • CONCLUSIONS: The study suggests improved outcomes in older adults with AML who undergo remission induction therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / mortality
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Case-Control Studies. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Remission Induction. Salvage Therapy. Survival Rate

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724726.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Prescot AP, Dzik-Jurasz AS, Leach MO, Sirohi B, Powles R, Collins DJ: Localized COSY and DQF-COSY 1H-MRS sequences for investigating human tibial bone marrow in vivo and initial application to patients with acute leukemia. J Magn Reson Imaging; 2005 Oct;22(4):541-8
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized COSY and DQF-COSY 1H-MRS sequences for investigating human tibial bone marrow in vivo and initial application to patients with acute leukemia.
  • Localized 2D 1H-MRS data were obtained from the bone marrow of healthy controls (N = 6), patients presenting with acute leukemia (N = 6) and patients with acute leukemia in remission (N = 4).
  • [MeSH-major] Bone Marrow / chemistry. Leukemia / metabolism. Lipids / analysis. Magnetic Resonance Spectroscopy / methods. Tibia / metabolism
  • [MeSH-minor] Acute Disease. Adult. Female. Humans. Male. Middle Aged. Phantoms, Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16161078.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipids
  •  go-up   go-down


5. Corey SJ, Elopre M, Weitman S, Rytting ME, Robinson LJ, Rumelhart S, Goldman FD: Complete remission following clofarabine treatment in refractory juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol; 2005 Mar;27(3):166-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission following clofarabine treatment in refractory juvenile myelomonocytic leukemia.
  • Juvenile myelomonocytic leukemia (JMML) is the most common myeloproliferative/myelodysplastic disorder seen in children.
  • The treatment of choice, allogeneic stem cell transplantation, provides the only known cure for the disease, but relapse after transplant is common.
  • The authors describe a 5-year-old boy diagnosed at age 34 months with JMML that evolved to acute myeloid leukemia.
  • Initial treatment consisted of fludarabine and cis-retinoic acid therapy, followed by a matched sibling bone marrow transplant.
  • After the second relapse, he received the farnesyltransferase inhibitor R115777 (tipifarnib, Zarnestra), but the leukemia persisted.
  • After three courses, he attained a remission marrow with 5% blasts and disappearance of the 5q- and 9q- cytogenetic abnormalities.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arabinonucleosides / therapeutic use. Drug Resistance, Neoplasm. Leukemia, Myelomonocytic, Chronic / drug therapy
  • [MeSH-minor] Adenine Nucleotides. Bone Marrow Transplantation. Child. Humans. Male. Neoplasm Recurrence, Local / drug therapy. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Juvenile Myelomonocytic Leukemia (JMML).
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15750451.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine
  •  go-up   go-down


6. Siennicka J, Trzcińska A, Rosińska M, Litwińska B: Seroprevalence of varicella-zoster virus in Polish population. Przegl Epidemiol; 2009;63(4):495-9
MedlinePlus Health Information. consumer health - Chickenpox.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since 1999, the varicella vaccine is licensed in Poland and recommended for use in adults without history of a varicella infection, and in children and young adults with remission of acute leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20120946.001).
  • [ISSN] 0033-2100
  • [Journal-full-title] Przegla̧d epidemiologiczny
  • [ISO-abbreviation] Przegl Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Chickenpox Vaccine; 0 / Immunoglobulin G
  •  go-up   go-down


7. Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE, Vij R, Blum W: Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood; 2009 Jan 29;113(5):1002-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.
  • Patients with acute myeloid leukemia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity.
  • Lenalidomide is a candidate for study in AML based on its clinical activity in a related disorder, myelodysplastic syndrome (MDS), with the 5q- chromosomal abnormality.
  • We report induction of sustained morphologic and cytogenetic complete remission in 2 older AML patients treated with high-dose, single-agent lenalidomide; each patient had trisomy 13 as the sole cytogenetic abnormality.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Chromosomes, Human, Pair 13 / genetics. Leukemia, Myeloid, Acute / drug therapy. Thalidomide / analogs & derivatives. Trisomy / genetics
  • [MeSH-minor] Aged. Humans. Male. Remission Induction / methods

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Trisomy 13.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Nature. 2008 Jan 17;451(7176):335-9 [18202658.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3063-7 [12384400.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] CA Cancer J Clin. 2002 Nov-Dec;52(6):363-71 [12469764.001]
  • [Cites] Blood. 1990 Oct 15;76(8):1614-21 [1698482.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] N Engl J Med. 2005 Feb 10;352(6):549-57 [15703420.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1154-63 [15870183.001]
  • [Cites] Leukemia. 2006 Mar;20(3):426-32 [16424866.001]
  • [Cites] Semin Hematol. 2006 Apr;43(2):89-95 [16616042.001]
  • [Cites] Blood. 2006 Jul 1;108(1):63-73 [16522815.001]
  • [Cites] N Engl J Med. 2006 Oct 5;355(14):1456-65 [17021321.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3458-64 [16840727.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1908-15 [17488990.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1123-6 [17650443.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1308-16 [17485549.001]
  • [Cites] Cancer. 2007 Nov 1;110(9):1900-10 [17786921.001]
  • [Cites] Blood. 2008 Jan 1;111(1):86-93 [17893227.001]
  • [Cites] Semin Hematol. 2002 Jul;39(3 Suppl 2):4-10 [12214287.001]
  • (PMID = 18824593.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00466895/ NCT00546897
  • [Grant] United States / NCI NIH HHS / CA / K23 CA120708; United States / NCI NIH HHS / CA / K23CA120708
  • [Publication-type] Case Reports; Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  • [Other-IDs] NLM/ PMC2947363
  •  go-up   go-down


8. Roboz GJ, Ritchie EK, Curcio T, Provenzano J, Carlin R, Samuel M, Wittenberg B, Mazumdar M, Christos PJ, Mathew S, Allen-Bard S, Feldman EJ: Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer; 2008 Nov 1;113(9):2504-11
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
  • BACKGROUND: Acute myeloid leukemia (AML) carries a dismal prognosis in older patients.
  • Of 64 patients who had pathologically confirmed AML, excluding patients with acute promyelocytic leukemia and using World Health Organization criteria, the median age was 71 years, 10 patients (16%) had treatment-related AML, 40 patients (63%) had an antecedent myelodysplastic syndrome or myeloproliferative disorder, and 35 patients (55%) had unfavorable cytogenetics.
  • RESULTS: Complete remission was achieved in 21 of 61 patients (34%), including 15 of 50 patients (30%) who had secondary or treatment-related AML, 10 of 33 patients (30%) who had unfavorable cytogenetics, and 6 of 34 patients (18%) who had a poor baseline performance status.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Arsenicals / administration & dosage. Cytarabine / administration & dosage. Female. Humans. Leukemia, Promyelocytic, Acute. Male. Middle Aged. Oxides / administration & dosage. Prognosis. Remission Induction. Survival Rate


9. McKenzie SB: Advances in understanding the biology and genetics of acute myelocytic leukemia. Clin Lab Sci; 2005;18(1):28-37
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in understanding the biology and genetics of acute myelocytic leukemia.
  • Acute myelocytic leukemia (AML) is a malignant neoplasm of hematopoietic cells characterized by an abnormal proliferation of myeloid precursor cells, decreased rate of self-destruction and an arrest in cellular differentiation.
  • In the United States, there are about 10,000 new cases of AML and 7,000 deaths in those with an AML diagnosis per year.
  • Current molecular studies of AML demonstrate that it is a heterogeneous disorder of the myeloid cell lineage.
  • Also discussed are how these advances have impacted the classification, selection of therapy, and definition of complete remission in AML.
  • Promyelocytic leukemia will be discussed in detail as this AML subtype reveals how our understanding of the biology and genetics of the disease has led to targeted therapy that results in a cure in up to 80% of patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Leukemia, Myeloid, Acute / genetics
  • [MeSH-minor] Cytogenetics. Humans. Immunophenotyping. Leukemia, Promyelocytic, Acute / etiology. Leukemia, Promyelocytic, Acute / genetics. Molecular Biology. Mutation. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics. Remission Induction. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Lab Sci. 2005 Summer;18(3):149
  • (PMID = 15747784.001).
  • [ISSN] 0894-959X
  • [Journal-full-title] Clinical laboratory science : journal of the American Society for Medical Technology
  • [ISO-abbreviation] Clin Lab Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  • [Number-of-references] 49
  •  go-up   go-down


10. Togashi Y, Sakoda H, Sugahara H, Asagoe K, Matsuzawa Y: [Loeys-Dietz syndrome with acute myeloid leukemia]. Rinsho Ketsueki; 2008 Aug;49(8):664-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Loeys-Dietz syndrome with acute myeloid leukemia].
  • Furthermore, karyotype analysis of bone marrow cells showed t(11;19)(q23;p13.1) and MLL abnormality was detected on RT-PCR A diagnosis of acute myeloid leukemia (M4) with 11q23 (MLL) abnormality was made.
  • Loeys-Dietz syndrome is a Marfan-like congenital connective tissue disorder caused by a heterozygous missense mutation of a TGF-beta receptor I or II gene.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Marfan Syndrome / complications. Marfan Syndrome / genetics
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Humans. Idarubicin / administration & dosage. Male. Middle Aged. Mutation, Missense. Receptors, Transforming Growth Factor beta / genetics. Remission Induction. Translocation, Genetic

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Loeys-Dietz Syndrome.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Marfan Syndrome.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18800617.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Receptors, Transforming Growth Factor beta; 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


11. Nishimoto N, Imai Y, Ueda K, Nakagawa M, Shinohara A, Ichikawa M, Nannya Y, Kurokawa M: T cell acute lymphoblastic leukemia arising from familial platelet disorder. Int J Hematol; 2010 Jul;92(1):194-7
MedlinePlus Health Information. consumer health - Platelet Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T cell acute lymphoblastic leukemia arising from familial platelet disorder.
  • Familial platelet disorder (FPD) is a rare autosomal dominant disorder which causes moderate thrombocytopenia with or without impaired platelet function.
  • Patients have a propensity to develop acute myeloid leukemia (AML), and various types of second hits have been postulated in the evolution to AML.
  • However, only a few cases of acute lymphoblastic leukemia (ALL) have been reported thus far.
  • The proband of the family developed AML and her son had ALL of the T cell lineage.
  • This translocation was not seen in any other affected members of the family or in the bone marrow sample of this patient in complete remission.
  • Taken together, t(1;7)(p34.1;q22) is thought to be one of the somatic second hits that predisposes FPD to acute leukemia with T cell phenotype.
  • [MeSH-major] Blood Platelet Disorders / complications. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20549580.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit
  •  go-up   go-down


12. Erba HP, Kantarjian HM, Claxton DF, Arellano M, Lyons RM, Kovacsovics TJ, Gabrilove J, Eckert S, Faderl S: Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor(s). J Clin Oncol; 2009 May 20;27(15_suppl):7062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor(s).
  • : 7062 Background: The CLASSIC II trial has previously reported an independently confirmed overall remission rate of 46% (38% CR and 8% CRp) and 30- and 60-day mortality rates of 9.8% and 16.1%, respectively (Blood 112: 558, 2008).
  • We now report updated duration of remission (DOR), disease-free survival (DFS), and overall survival (OS).
  • METHODS: Single arm, multi-center, phase II, open-label, 2-stage study of patients with untreated AML, ≥60 years old, and at least one adverse prognostic factor: age ≥70 years, antecedent hematologic disorder (AHD), PS = 2, and/or intermediate/unfavorable risk karyotype.
  • Patients were followed for at least 6 months past remission (CR/CRp).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961436.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Takami A, Okumura H, Yamazaki H, Kami M, Kim SW, Asakura H, Endo T, Nishio M, Minauchi K, Kumano K, Sugimori N, Mori S, Takemoto Y, Shimadoi S, Ozaki J, Takaue Y, Nakao S: Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation. Int J Hematol; 2005 Dec;82(5):449-55
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation.
  • To determine whether induction of graft-versus-host disease (GVHD) improves the outcome of acute relapsed leukemia after stem cell transplantation (SCT), we used high-dose cytarabine (ara-C) followed by infusions of donor-derived buffy coats containing peripheral blood stem cells to treat 12 patients with relapsed leukemia.
  • Donor lymphocyte infusion (DLI) was repeated at least twice over a 5-week interval for patients in whom grade II to IV acute GVHD did not develop after the first DLI.
  • Grade II to IV acute GVHD developed in 4 (33%) of the patients.
  • Chronic GVHD developed in 3 patients, 2 of whom had not experienced acute GVHD.
  • Four (67%) of the 6 patients who developed grade II to IV acute and/or chronic GVHD after DLI responded, but none of the other 6 patients responded.
  • Four (33%) of the patients (2 with acute myelogenous leukemia [AML] and 2 with acute lymphoblastic leukemia [ALL]) achieved complete remission lasting longer than 4 months after the first DLI, but 3 of them had relapses in bone sites.
  • These findings indicate that high-dose ara-C combined with megadose DLI may produce durable remission of acute leukemia that has relapsed after SCT when GVHD is induced.
  • The low induction rate of GVHD and extramedullary relapse after remission is achieved with DLI are problems yet to be solved.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Cytarabine / administration & dosage. Graft vs Host Disease / therapy. Leukemia / therapy. Lymphocyte Transfusion. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prospective Studies. Recurrence. Remission Induction. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533751.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


14. Papalambros E, Felekouras E, Karavokyros IG, Diamantis T, Androulaki A, Boutsis D, Sigala F, Tsavaris N, Pangalis G: Acute abdomen as initial manifestation of M4 - acute non-lymphocytic leukemia. J BUON; 2005 Apr-Jun;10(2):277-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute abdomen as initial manifestation of M4 - acute non-lymphocytic leukemia.
  • Visceral involvement in acute non-lymphocytic leukemia (ANLL) seldom precedes hematological manifestation.
  • We report on a patient with M4 - ANLL presenting with acute abdomen without any evidence of blood disorder.
  • Chemotherapy achieved a complete but short remission.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343343.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


15. Bacchetta J, Douvillez B, Warin L, Girard S, Pagès MP, Rebaud P, Bertrand Y: [Blueberry Muffin Baby and spontaneous remission of neonatal leukaemia]. Arch Pediatr; 2008 Aug;15(8):1315-9
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Blueberry Muffin Baby and spontaneous remission of neonatal leukaemia].
  • Blueberry Muffin baby is a rare neonatal skin disorder.
  • We report on a newborn presenting with Blueberry Muffin syndrome and an adrenal mass which lead to the diagnosis of neuroblastoma.
  • Actually, it corresponded to an acute monoblastic leukaemia with an adrenal localization and a cerebrospinal fluid involvement.
  • Leukaemia should always be considered in such patients, even in the absence of blasts on white blood cells count and bone marrow examination, as in this patient.
  • This observation was also unusual due to spontaneous remission.
  • The patient is in complete remission at 1 year follow-up.
  • [MeSH-major] Leukemia, Myeloid, Acute. Skin Diseases / congenital
  • [MeSH-minor] Diagnosis, Differential. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Remission, Spontaneous. Time Factors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18595669.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


16. Kwaan HC, Rego EM: Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia. Semin Thromb Hemost; 2010 Nov;36(8):917-24
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia.
  • Serious bleeding and thrombotic complications are frequent in acute promyelocytic leukemia (APL) and are major causes of morbidity and mortality.
  • In this article, the hemostatic dysfunction in this disorder is briefly reviewed.
  • MP bearing tissue factor, profibrinolytic factors (tissue plasminogen activator and annexin A2), and the antifibrinolytic factor plasminogen activator inhibitor type 1 were measured using flow cytometry.
  • The cellular origin of the MP was identified by specific cell surface markers.
  • Comparison of the various populations of MP was made between samples collected at the time of diagnosis with those collected at molecular remission.
  • [MeSH-major] Cell-Derived Microparticles / physiology. Hemostasis. Leukemia, Promyelocytic, Acute / blood

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Thieme Medical Publishers.
  • (PMID = 21049391.001).
  • [ISSN] 1098-9064
  • [Journal-full-title] Seminars in thrombosis and hemostasis
  • [ISO-abbreviation] Semin. Thromb. Hemost.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


17. Bacher U, Schnittger S, Haferlach T: Molecular genetics in acute myeloid leukemia. Curr Opin Oncol; 2010 Nov;22(6):646-55
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetics in acute myeloid leukemia.
  • PURPOSE OF REVIEW: Acute myeloid leukemia (AML) is a highly heterogeneous disorder being composed of various genetically defined subtypes.
  • RECENT FINDINGS: A molecular data set based on mutations of the NPM1, FLT3, and CEBPA genes and the MLL-PTD provides a prognostically relevant risk stratification that can support the decision pro or con an allogeneic hematopoietic stem cell transplantation in first remission.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20805748.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


18. Ventura F, Pereira T, da Luz Duarte M, Marques H, Pardal F, Brito C: Indeterminate cell histiocytosis in association with acute myeloid leukemia. Dermatol Res Pract; 2010;2010:569345

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indeterminate cell histiocytosis in association with acute myeloid leukemia.
  • Indeterminate cell histiocytosis (ICH) is a rare proliferative disorder, in which the predominant cells share morphologic and immunophenotypic features from both Langerhans and non-Langerhans cell histiocytosis.
  • Nevertheless, one month after remission, he developed an acute myeloid leukemia of the subtype monocytic leukemia (M5).
  • We present this case because apart of being rare it joins the effectiveness of thalidomide and the association with an acute monocytic leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1489-99 [17369076.001]
  • [Cites] Br J Dermatol. 2007 Jun;156(6):1357-61 [17459045.001]
  • [Cites] J Am Acad Dermatol. 2007 Feb;56(2):302-16 [17097374.001]
  • [Cites] J Cutan Pathol. 2005 Sep;32(8):552-60 [16115054.001]
  • [Cites] J Am Acad Dermatol. 1986 Oct;15(4 Pt 1):591-7 [3095403.001]
  • [Cites] Eur J Haematol. 2005 Feb;74(2):172-4 [15654911.001]
  • [Cites] Ann N Y Acad Sci. 1999 Apr 30;872:256-62; discussion 262-4 [10372128.001]
  • [Cites] Br J Dermatol. 1996 Mar;134(3):525-32 [8731682.001]
  • [Cites] Br J Dermatol. 2005 Jul;153(1):206-7 [16029353.001]
  • (PMID = 20672000.001).
  • [ISSN] 1687-6113
  • [Journal-full-title] Dermatology research and practice
  • [ISO-abbreviation] Dermatol Res Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2905718
  •  go-up   go-down


19. Abdool A, Yeh CH, Kantarjian H, O'Brien S, Bruey J, Giles F, Albitar M: Circulating CD33 and its clinical value in acute leukemia. Exp Hematol; 2010 Jun;38(6):462-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating CD33 and its clinical value in acute leukemia.
  • OBJECTIVE: CD33 is a cell surface antigen for committed myelomonocytic lineage.
  • We explored the potential of detecting CD33 as cell-free circulating protein in patients with leukemia.
  • MATERIALS AND METHODS: We developed a quantitative bead-based immunoflow cytometry assay to measure cell-free circulating CD33 (cCD33) levels in the plasma of patients with acute leukemia, and correlated these results with corresponding clinical behavior.
  • We measured cCD33 levels in the plasma of 48 healthy subjects and in patients with acute myelogenous leukemia (n = 98), acute lymphoblastic leukemia (n = 46), myelodysplastic syndrome (MDS) (n = 50), and myeloproliferative disorder (n = 49).
  • RESULTS: Patients with acute myeloid leukemia and myeloproliferative disorders had significantly higher concentrations of cCD33 than the other patient groups and normal individuals (p = 0.0001), and among these groups, MDS patients displayed the lowest cCD33 levels (p = 0.02).
  • Circulating CD33 values correlated positively with the CD33(+) blast cell counts in these patients.
  • While there was no correlation between cCD33 levels and survival in acute myelogenous leukemia and MDS, higher cCD33 plasma concentrations did correlate with shorter survival in acute lymphoblastic leukemia (p = 0.03), and with shorter complete remission duration in acute myelogenous leukemia (p = 0.04) and MDS (p = 0.03).
  • [MeSH-major] Antigens, CD / blood. Antigens, Differentiation, Myelomonocytic / blood. Leukemia, Myeloid, Acute / blood
  • [MeSH-minor] Acute Disease. Case-Control Studies. Cell Line, Tumor. Cell-Free System. Flow Cytometry. Humans. Sialic Acid Binding Ig-like Lectin 3

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20362641.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3
  •  go-up   go-down


20. Sahin F, Sercan Z, Ertan Y, Ocakci S, Ay E, Vural F, Yuksel E, Tombuloglu M, Saydam G: Rapid transformation of atypical myeloproliferative disorder with consistent t(8;13) to B-cell acute lymphoblastic leukemia: a case report. Hematology; 2007 Dec;12(6):489-92
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid transformation of atypical myeloproliferative disorder with consistent t(8;13) to B-cell acute lymphoblastic leukemia: a case report.
  • 8p11 myeloproliferative syndrome (EMS; also known as the stem cell leukemia syndrome-SCLL) is a rare atypical myeloproliferative disorder associated with chromosomal abnormalities involving the 8p11 chromosomal band.
  • Disease phenotype associated with this translocation has some typical features such as poor prognosis, and transformation to mainly acute leukemia and non-Hodgkin lymphoma; commonly with a T-cell phenotype in which obtaining and maintenance of remission is difficult by conventional chemotherapy.
  • We hereby present a case diagnosed as atypical chronic myeloproliferative disease with consistent t(8;13)(p12;q12) and transformed rapidly to pre-B-cell acute lymphoblastic leukemia which is a rare clinical presentation.
  • [MeSH-major] Burkitt Lymphoma / etiology. Cell Transformation, Neoplastic. Myeloproliferative Disorders / pathology. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852454.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Abdel-Wahab O, Levine RL: Recent advances in the treatment of acute myeloid leukemia. F1000 Med Rep; 2010 Jul 22;2:55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in the treatment of acute myeloid leukemia.
  • Acute myeloid leukemia (AML) is a disorder with significant molecular and clinical heterogeneity.
  • Lastly, we review a recent assessment of the role of allogeneic hematopoietic stem cell transplantation in AML in first complete remission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Sep 30;341(14):1051-62 [10502596.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):562-9 [20026804.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3575-83 [11739159.001]
  • [Cites] Eur J Haematol. 2004 Jan;72(1):38-44 [14962261.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1513-22 [17082009.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1114-24 [17315155.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • [Cites] Blood. 2009 Jul 2;114(1):144-7 [19420352.001]
  • [Cites] N Engl J Med. 2009 May 28;360(22):2289-301 [19474426.001]
  • [Cites] Nat Genet. 2009 Jul;41(7):838-42 [19483684.001]
  • [Cites] JAMA. 2009 Jun 10;301(22):2349-61 [19509382.001]
  • [Cites] N Engl J Med. 2009 Sep 10;361(11):1058-66 [19657110.001]
  • [Cites] Biologics. 2008 Sep;2(3):491-500 [19707379.001]
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1235-48 [19776405.001]
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1249-59 [19776406.001]
  • [Cites] Leukemia. 2010 Feb;24(2):469-73 [19865112.001]
  • [Cites] Blood. 2010 Jan 21;115(3):453-74 [19880497.001]
  • [Cites] Cancer Cell. 2010 Jan 19;17(1):13-27 [20060365.001]
  • [Cites] Cancer Res. 2010 Jan 15;70(2):447-52 [20068184.001]
  • [Cites] Cancer Cell. 2010 Mar 16;17(3):225-34 [20171147.001]
  • [Cites] Blood. 1990 Jan 1;75(1):27-32 [2403818.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3244-54 [11432892.001]
  • (PMID = 20798782.001).
  • [ISSN] 1757-5931
  • [Journal-full-title] F1000 medicine reports
  • [ISO-abbreviation] F1000 Med Rep
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / K08 HL082677; United States / NCI NIH HHS / CA / U54 CA143798; United States / NCI NIH HHS / CA / U54 CA143798-01
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M, Petersdorf S, Shami PJ, Yeager AM, Eckert S, Abichandani R, Faderl S: Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol; 2010 Feb 1;28(4):549-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.
  • PURPOSE: This phase II study assessed clofarabine monotherapy in older adults (>or= 60 years of age) with untreated acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor.
  • The primary end point was overall remission rate (ORR; ie, complete remission [CR] plus CR with incomplete platelet recovery [CRp]).
  • ORR by unfavorable prognostic factor was 39% for patients >or= 70 years of age; 32% for Eastern Cooperative Oncology Group (ECOG) performance status 2; 51% for antecedent hematologic disorder; 54% for intermediate karyotype; 42% for unfavorable karyotype; and 48%, 51%, and 38% for one, two, and three risk factors, respectively.
  • Median duration of remission was 56 weeks (95% CI, 33 to not estimable).
  • The most common non-laboratory drug-related toxicities (>or= 20% patients) were nausea, febrile neutropenia, vomiting, diarrhea, rash, and fatigue.
  • [MeSH-major] Adenine Nucleotides / therapeutic use. Antineoplastic Agents / therapeutic use. Arabinonucleosides / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Remission Induction. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Feb 1;28(4):521-3 [20026796.001]
  • (PMID = 20026805.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine
  •  go-up   go-down


23. Sivendran S, Gruenstein S, Malone AK, Najfeld V: Ring chromosome 18 abnormality in acute myelogenous leukemia: the clinical dilemma. J Hematol Oncol; 2010;3:25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ring chromosome 18 abnormality in acute myelogenous leukemia: the clinical dilemma.
  • Considering that ring chromosomes are rare in acute myelogenous leukemia (AML), it is difficult to risk stratify patient prognosis, particularly when the ring chromosome occurs as the sole abnormality.
  • The patient received induction chemotherapy and subsequent allogeneic cord blood transplant from a sex-matched donor, and remained in hematologic and cytogenetic remission for 120 days post transplant.
  • Soon after, he developed post transplant lymphoproliferative disorder and died of multi-organ failure.
  • Although r(18) chromosomal abnormalities were not classified in the recent updated evidence-and expert opinion-based recommendations for the diagnosis and management of AML (likely due to the small number of reported cases), the patient was treated as high risk with stem cell transplantation.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 18 / genetics. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy. Ring Chromosomes
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cord Blood Stem Cell Transplantation. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Treatment Outcome


24. Parker TM, Klaassen RJ, Johnston DL: Spontaneous remission of myelodysplastic syndrome with monosomy 7 in a young boy. Cancer Genet Cytogenet; 2008 Apr 15;182(2):122-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of myelodysplastic syndrome with monosomy 7 in a young boy.
  • Myelodysplastic syndrome (MDS) is a clonal hematopoietic disorder that often results in progression to acute myeloid leukemia (AML), particularly when additional genetic abnormalities are present, such as monosomy 7.
  • Spontaneous remission has occurred in a small number of cases.
  • In the present case, a previously healthy 3-year-old boy diagnosed with MDS and monosomy 7 achieved spontaneous remission without intervention 30 months after initial diagnosis.
  • Such findings highlight the need to monitor patients closely for evidence of spontaneous remission.
  • [MeSH-minor] Child, Preschool. Cytogenetic Analysis. Humans. In Situ Hybridization, Fluorescence. Male. Prognosis. Remission, Spontaneous


25. Szotkowski T, Rohon P, Zapletalova L, Sicova K, Hubacek J, Indrak K: Secondary acute myeloid leukemia - a single center experience. Neoplasma; 2010;57(2):170-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary acute myeloid leukemia - a single center experience.
  • Secondary acute myeloid leukemia (sAML) may arise from the previous clonal disorder of hematopoiesis, usually from myelodysplastic syndrome (MDS) or from chronic myeloproliferative neoplasia (cMPN) or after exposure to a leukemogenic agent (previous chemotherapy or radiotherapy, some immunosuppressive drugs or environmental leukemogenic agents).
  • Secondary origin of AML is associated with unfavorable prognosis and it is not considered to be conventionally curable (with the exception of secondary acute promyelocytic leukemia).
  • Of those, 430 patients were diagnosed as having primary AML; in 86 patients, sAML transformed from myelodysplastic syndrome and 58 patients were followed or treated for various malignancies or were treated with potentially leukemogenic agents because of non-malignant disorders.
  • Complete hematologic remission is achieved with a low probability, relapse of the disease occurs frequently and overall survival is worse in almost all prognostic subgroups.
  • With the exception of secondary acute promyelocytic leukemia, the prognosis of which does not differ from very good prognosis of the primary forms, secondary AML is not considered a conventionally curable disease.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Myelodysplastic Syndromes / complications. Myeloproliferative Disorders / complications. Neoplasm Recurrence, Local / etiology. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adult. Aged. Chronic Disease. Female. Humans. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult


26. Fouyssac F, Salmon A, Mansuy L, Schmitt C, Bordigoni P, Chastagner P: [Treatment of febrile neutropenia episodes in children, with a piperacillin-tazobactam and netilmicin combination]. Med Mal Infect; 2005 Jun;35(6):357-62
Hazardous Substances Data Bank. NETILMICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Traitement des épisodes de neutropénie fébrile chimio-induite de l'enfant par l'association pipéracilline-tazobactam et nétilmicine.
  • RESULTS: Sixty-nine episodes were assessable, corresponding to 41 patients, treated for a solid tumour (29), an acute leukaemia in remission (11), or a metabolic disease (1).
  • [MeSH-minor] Adolescent. Anti-Bacterial Agents / administration & dosage. Anti-Bacterial Agents / therapeutic use. Antineoplastic Agents / adverse effects. Child. Child, Preschool. Clinical Trials as Topic. Drug Combinations. Drug Evaluation. Escherichia coli Infections / drug therapy. Female. Hematopoietic Stem Cell Transplantation. Humans. Immunocompromised Host. Infant. Male. Neoplasms / drug therapy. Penicillanic Acid / administration & dosage. Penicillanic Acid / analogs & derivatives. Penicillanic Acid / therapeutic use. Piperacillin / administration & dosage. Piperacillin / therapeutic use. Postoperative Complications / drug therapy. Retrospective Studies. Treatment Outcome. Urinary Tract Infections / drug therapy

  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • MedlinePlus Health Information. consumer health - Fever.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982848.001).
  • [ISSN] 0399-077X
  • [Journal-full-title] Médecine et maladies infectieuses
  • [ISO-abbreviation] Med Mal Infect
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents; 0 / Drug Combinations; 157044-21-8 / piperacillin, tazobactam drug combination; 4O5J85GJJB / Netilmicin; 87-53-6 / Penicillanic Acid; X00B0D5O0E / Piperacillin
  • [Number-of-references] 23
  •  go-up   go-down


27. Sumi M, Tauchi T, Takaku T, Ohyashiki JH, Ohyashiki K: [Successful treatment with interferon-alpha in a case of acute myeloid leukemia with del (20q) following polycythemia vera]. Rinsho Ketsueki; 2005 Nov;46(11):1208-12
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment with interferon-alpha in a case of acute myeloid leukemia with del (20q) following polycythemia vera].
  • Polycythemia vera (PV) is a hematopoietic stem cell clonal disorder, 5 to approximately 10% of which will evolve into acute leukemia.
  • A 73-year-old woman was given a diagnosis of PV 17 years previously.
  • She achieved not only a hematologic remission, but also cytogenetic remission after interferon (IFN)-alpha treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Chromosomes, Human, Pair 20 / genetics. Interferon-alpha / therapeutic use. Leukemia, Myeloid, Acute / etiology. Polycythemia Vera / complications
  • [MeSH-minor] Cell Transformation, Neoplastic. Chromosome Deletion. Disease Progression. Female. Humans. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Polycythemia vera.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440805.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


28. Al-Sobhi EM, Jeha TM, Al-Taher MI: Granulocytic sarcoma causing cord compression in a pregnant woman with acute myeloid leukemia and t(8;21). Saudi Med J; 2008 Nov;29(11):1658-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma causing cord compression in a pregnant woman with acute myeloid leukemia and t(8;21).
  • Most frequently they occur in acute myeloid leukemia (AML), myeloproliferative disorder, and myelodysplasia.
  • She had a normal baby, and achieved second remission post-chemotherapy.
  • [MeSH-major] Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Leukemia, Myeloid, Acute / complications. Pregnancy Complications, Neoplastic / pathology. Sarcoma, Myeloid / pathology. Translocation, Genetic. Umbilical Cord / pathology


29. Gupta V, Chun K, Yi QL, Minden M, Schuh A, Wells R, Brandwein J: Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer; 2005 May 15;103(10):2082-90
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
  • BACKGROUND: The objectives of the current study were to evaluate the outcome of patients > or = 60 years with acute myeloid leukemia (AML) treated uniformly with high-dose daunorubicin containing induction and modified high-dose cytosine arabinoside containing postremission therapy, and to identify factors predictive of complete disease remission (CR) and survival.
  • METHODS: Between 1998 and 2002, the authors treated 117 newly diagnosed patients (acute promyelocytic leukemia excluded) with AML > or = 60 years (median, 67 years; range, 60-82 years).
  • Karyotype (Medical Research Council classification) at diagnosis was categorized as good risk (n = 3), intermediate risk (n = 69), adverse risk (n = 26), and suboptimal/not done (n = 19).
  • In a multivariate model, adverse-risk cytogenetics, previous history of myelodysplastic syndrome or antecedent hematologic disorder, and high leukocyte count (> 30 x 10(9)/L) were independent adverse prognostic factors for survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Age Factors. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Disease-Free Survival. Female. Follow-Up Studies. Hematologic Diseases / complications. Humans. Karyotyping. L-Lactate Dehydrogenase / analysis. Leukocyte Count. Male. Middle Aged. Myelodysplastic Syndromes / complications. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15830348.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 1.1.1.27 / L-Lactate Dehydrogenase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


30. Erikci AA, Ozturk A, Karagoz B, Bilgi O, Turken O, Top C, Kandemir EG: Results of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemia. Hematology; 2008 Oct;13(5):289-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemia.
  • It has been shown that abnormal cytokine production together with apoptosis are major contributors to the cytopenias associated with the disorder.
  • As the interaction of cytokines plays a role in the pathogenesis, suppression of the cytokine production by the administration of the combination of pentoxifylline, ciprofloxacin, and dexamethasone (PCD combination) has resulted in the correction of at least some aspects of the cytopenias in the majority of patients and in complete hematologic remission in a small percentage.
  • In this study we report the results of combination therapy of amifostine and PCD in 12 patients with MDS and acute myeloid leukemia (AML).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy


31. Ciccone M, Rigolin GM, Viglione GM, Borrelli M, Serino ML, Cuneo A: Thrombosis of the cerebral veins and sinuses in acute promyelocytic leukemia after all-trans retinoic acid treatment: a case report. Blood Coagul Fibrinolysis; 2008 Oct;19(7):721-3
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thrombosis of the cerebral veins and sinuses in acute promyelocytic leukemia after all-trans retinoic acid treatment: a case report.
  • Thrombosis of the cerebral veins or sinuses is a rare cerebrovascular disorder, which seldom represents a complication of acute promyelocytic leukemia.
  • We report a case of a 35-year-old woman affected by acute promyelocytic leukemia, who developed massive thrombosis of the cerebral sinuses and veins when she was in complete morphological and molecular remission after all-trans retinoic acid and idarubicin treatment.
  • [MeSH-major] Cerebral Hemorrhage / chemically induced. Leukemia, Promyelocytic, Acute / drug therapy. Sinus Thrombosis, Intracranial / chemically induced. Thrombosis / chemically induced. Tretinoin / adverse effects

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18832917.001).
  • [ISSN] 0957-5235
  • [Journal-full-title] Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • [ISO-abbreviation] Blood Coagul. Fibrinolysis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5688UTC01R / Tretinoin; ZRP63D75JW / Idarubicin
  •  go-up   go-down


32. Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M, Ottmann OG: Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer; 2005 Dec 15;104(12):2717-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
  • BACKGROUND: Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, induced in vitro differentiation of primary acute myeloid leukemia (AML) blasts, an effect enhanced by all-trans retinoic acid (ATRA).
  • No patient achieved complete remission, one with de novo AML had a minor response, and two patients with secondary AML arising from myeloproliferative disorder (MPD) achieved a partial remission and clearance of PB blasts, respectively.
  • The latter responses were accompanied by profound granulocytosis and erythrocytosis in both patients, reminiscent of the response pattern known from ATRA treatment of acute promyelocytic leukemia.
  • CONCLUSIONS: Treatment with VPA/ATRA results in transient disease control in a subset of patients with AML that has evolved from a myeloproliferative disorder but not in patients with a primary or MDS-related AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / drug therapy. Tretinoin / administration & dosage. Valproic Acid / administration & dosage

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16294345.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5688UTC01R / Tretinoin; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


33. Licinio J: The experience of bipolar disorder: a personal perspective on the impact of mood disorder symptoms. Mol Psychiatry; 2005 Sep;10(9):827-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The experience of bipolar disorder: a personal perspective on the impact of mood disorder symptoms.
  • This is a personal perspective on bipolar disorder, entirely written by a well-informed patient who is a successful mental heath professional.
  • My struggle with bipolar disorder forced me to leave an Ivy League university and endure six hospitalizations during my early adulthood.
  • For some diseases like acute lymphoblastic leukemia (ALL) of childhood, rates of remission and cure have been constantly advancing through better use of existing compounds.
  • [MeSH-major] Bipolar Disorder / genetics. Mood Disorders / genetics


34. Zander AR, Bacher U, Finke J: Allogeneic stem cell transplantation in acute myeloid leukemia: establishment of indications on the basis of individual risk stratification. Dtsch Arztebl Int; 2008 Sep;105(39):663-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation in acute myeloid leukemia: establishment of indications on the basis of individual risk stratification.
  • INTRODUCTION: Acute myeloid leukemia (AML) is a heterogeneous disorder with subtypes that differ considerably in morphology and in their underlying chromosomal and molecular aberrations, which, in turn, determine their prognosis.
  • The establishment of the indications for allogeneic stem cell transplantation (SCT) therefore requires individualized risk stratification based on a combination of multiple diagnostic methods, including cytogenetic and molecular genetic studies, and immunophenotyping, as well as the sensitivity of the disease to chemotherapy.
  • RESULTS: In patients with a high risk constellation-e.g., chromosome 7 anomalies, complex aberrations, or FLT3-length mutations-there is an indication for SCT in first remission.
  • The balanced translocations t(15;17) and t(8;21), and the inversion inv(16) are prognostically favorable and are thus not considered an indication for SCT in first remission.
  • The establishment of indications for stem cell transplantation also depends on the residual leukemic cell burden (minimal residual disease, MRD) as determined by the quantitative polymerase chain reaction or by flow cytometry, as well as an insufficient response to induction chemotherapy.
  • Reduced-dose conditioning, a new technique that lessens acute toxicity, has been found to be associated with a 30% to over 50% two-year survival rate when used in the treatment of chemotherapeutically unresponsive or relapsing AML.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Oct 15;102(8):2746-55 [12842988.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S100-1 [15124694.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1613-8 [12750167.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1232-40 [12714526.001]
  • [Cites] Ann Hematol. 2003 Jun;82(6):336-42 [12728337.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1480-4 [12697870.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):256-65 [12525517.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3254-61 [12149299.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Mar;15(1):137-58 [11987921.001]
  • [Cites] Br J Haematol. 2001 Jan;112(1):118-26 [11167792.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Br J Haematol. 2000 Sep;110(3):620-30 [10997974.001]
  • [Cites] Blood. 2008 Jul 15;112(2):415-25 [18451310.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):577-84 [18086801.001]
  • [Cites] Eur J Haematol. 2008 Mar;80(3):208-15 [18081718.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:453-9 [18024664.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4938-45 [17909197.001]
  • [Cites] Methods Mol Med. 2007;134:161-78 [17666750.001]
  • [Cites] Bone Marrow Transplant. 2007 Apr;39(8):461-9 [17322930.001]
  • [Cites] Lab Hematol. 2007;13(1):22-6 [17353179.001]
  • [Cites] Haematologica. 2007 Mar;92(3):315-22 [17339180.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Mar;20(1):29-37 [17336252.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2264-5; author reply 2265 [17312001.001]
  • [Cites] Bone Marrow Transplant. 2007 Jan;39(2):71-87 [17213849.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Lancet. 2006 Nov 25;368(9550):1894-907 [17126723.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3280-8 [16840728.001]
  • [Cites] Br J Haematol. 2006 Nov;135(4):438-49 [16965385.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1783-9 [16838027.001]
  • [Cites] Blood. 2006 Aug 1;108(3):836-46 [16597592.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1092-9 [16551971.001]
  • [Cites] Haematologica. 2006 Jun;91(6):833-6 [16769587.001]
  • [Cites] Leukemia. 2006 Jun;20(6):1103-8 [16541144.001]
  • [Cites] Leukemia. 2006 Jan;20(1):87-94 [16281071.001]
  • [Cites] Leukemia. 2006 Apr;20(4):707-14 [16482208.001]
  • [Cites] Best Pract Res Clin Haematol. 2006;19(2):329-32 [16516130.001]
  • [Cites] Methods Mol Med. 2006;125:163-75 [16502584.001]
  • [Cites] Bone Marrow Transplant. 2006 Mar;37(5):439-49 [16444286.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9387-93 [16314618.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3658-65 [16076872.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3B):1931-44 [16158928.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1652-8 [15742336.001]
  • [Cites] Bone Marrow Transplant. 2005 Apr;35(8):767-73 [15735660.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1969-78 [15632409.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):254-66 [15659725.001]
  • [Cites] Curr Opin Hematol. 2005 Jan;12(1):68-75 [15604894.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):559-62 [9827935.001]
  • [Cites] Bone Marrow Transplant. 1998 Jan;21(2):159-66 [9489633.001]
  • [Cites] Cancer. 1997 Dec 1;80(11 Suppl):2191-8 [9395033.001]
  • [Cites] Haematologica. 2004 Oct;89(10):1238-47 [15477210.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1380-90 [15201848.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Sep;16(3):409-17 [12935959.001]
  • (PMID = 19626214.001).
  • [ISSN] 1866-0452
  • [Journal-full-title] Deutsches Ärzteblatt international
  • [ISO-abbreviation] Dtsch Arztebl Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2700644
  • [Keywords] NOTNLM ; indications / leukemia treatment / molecular medicine / myelopathy / stem cell therapy
  •  go-up   go-down


35. Mizoguchi Y, Fujita N, Taki T, Hayashi Y, Hamamoto K: Juvenile myelomonocytic leukemia with t(7;11)(p15;p15) and NUP98-HOXA11 fusion. Am J Hematol; 2009 May;84(5):295-7
Genetic Alliance. consumer health - Juvenile Myelomonocytic Leukemia (JMML).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juvenile myelomonocytic leukemia with t(7;11)(p15;p15) and NUP98-HOXA11 fusion.
  • The t(7;11)(p15;p15) translocation has been reported as a rare and recurrent chromosomal abnormality in acute myeloid leukemia (AML) patients.
  • To date, t(7;11)(p15;p15) with NUP98-HOXA11 fusion has been reported only in one case of ph-negative chronic myeloid leukemia (CML).
  • Here, we report a case of a 3-year-old girl with juvenile myelomonocytic leukemia (JMML) carrying t(7;11)(p15;p15) abnormality with NUP98-HOXA11 fusion.
  • AML chemotherapy followed by bone marrow transplantation (BMT) was found to be effective in treating this disorder, and she remains in complete remission for 3 years after BMT.
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 7. Homeodomain Proteins / genetics. Leukemia, Myelomonocytic, Juvenile / genetics. Leukemia, Myelomonocytic, Juvenile / therapy. Nuclear Pore Complex Proteins / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation. Child, Preschool. Combined Modality Therapy. Female. Humans. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19338047.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Homeodomain Proteins; 0 / NUP98-HOXA11 fusion protein, human; 0 / Nuclear Pore Complex Proteins; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


36. Jackowska T, Steczowicz M, Pawelec K, Pacholska J: [Congenital leukaemia and transient myeloproliferative disorder: diagnostic difficulties--case reports]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):595-601
MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Congenital leukaemia and transient myeloproliferative disorder: diagnostic difficulties--case reports].
  • Congenital leukaemia occurs in only 0.8% of all cases of leukaemia in children.
  • Despite great progress in the treatment of childhood leukaemia, prognosis is still poor.
  • This type of leukaemia must be distinguished from leukaemic reactions and transient myeloproliferative disorder.
  • Transient myeloproliferative disorder is a rare condition in the neonatal period, connected with trisomy or other abnormalities of chromosome 21.
  • We present two cases: congenital leukaemia and transient myeloproliferative disorder.
  • The first patient was a boy in whom congenital myelomonoblastic leukaemia (M4 in FAB classification) was diagnosed at age of 6 weeks.
  • He was treated according to BFM-96 for acute myeloblasts leukaemia protocol, but there was no remission and he died of progressive congenital leukaemia after 4 months.
  • These cases confirm the difficulties in differentiation between congenital leukaemia and transient myeloproliferative disorder presented in literature.
  • In spite of the same haematological symptoms the only difference may be detection of nonhematopoietic tissue infiltration (skin and central nervous system) commonly occurring in congenital leukaemia or the presence of trisomy and other abnormalities of chromosome 21 in transient myeloproliferative disorder.
  • [MeSH-major] Leukemia, Lymphoid / congenital. Leukemia, Lymphoid / diagnosis. Leukemia, Myeloid, Acute / congenital. Leukemia, Myeloid, Acute / diagnosis. Myeloproliferative Disorders / congenital. Myeloproliferative Disorders / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Down Syndrome / complications. Down Syndrome / diagnosis. Fatal Outcome. Female. Humans. Infant, Newborn. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317890.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


37. Abuzayed B, Dashti R, Turk O, Kaynar MY: Aneurysmal frontal bone cyst in a child with history of acute lymphoblastic leukemia: a case of rare location and history. J Pediatr Hematol Oncol; 2010 Jan;32(1):e1-3
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aneurysmal frontal bone cyst in a child with history of acute lymphoblastic leukemia: a case of rare location and history.
  • The patient was diagnosed for acute lymphoblastic leukemia 5 years ago and had been treated.
  • The patient was under observation by the pediatric oncology clinic with remission state since 3 years.
  • A preoperative diagnosis of myeloproliferative disorder was made and it was surgically resected and cranioplasty with porous polyethylene sheets (Medpor, Porex Surgical Inc, GA) was performed in the same stage.
  • Although rare lesions, aneurysmal bone cysts must be considered in the differential diagnosis of calvarial mass lesions.
  • [MeSH-major] Bone Cysts, Aneurysmal / diagnosis. Bone Cysts, Aneurysmal / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Child. Diagnosis, Differential. Diagnostic Imaging. Female. Forehead. Frontal Bone / pathology. Humans. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19636268.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, Stone RM, Amrein PC: Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res; 2008 Mar 1;14(5):1446-54
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
  • PURPOSE: Proteasome inhibition results in cytotoxicity to the leukemia stem cell in vitro.
  • We conducted this phase I study to determine if the proteasome inhibitor bortezomib could be safely added to induction chemotherapy in patients with acute myelogenous leukemia (AML).
  • There were 22 patients of > or = 60 years with previously untreated AML (eight with prior myelodysplasia/myeloproliferative disorder or cytotoxic therapy).
  • Overall, 19 patients (61%) achieved complete remission (CR) and three had CR with incomplete platelet recovery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Leukemia, Myeloid, Acute / metabolism

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18316568.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA066996
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Boronic Acids; 0 / Pyrazines; 04079A1RDZ / Cytarabine; 69G8BD63PP / Bortezomib; ZRP63D75JW / Idarubicin
  •  go-up   go-down


39. Shin MG, Choi HW, Kim HR, Kim MJ, Baek HJ, Han DK, Kook H, Hwang TJ, Kim HJ, Kim SH, Shin JH, Suh SP, Ryang DW: Tetrasomy 21 as a sole acquired abnormality without GATA1 gene mutation in pediatric acute megakaryoblastic leukemia: a case report and review of the literature. Leuk Res; 2008 Oct;32(10):1615-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tetrasomy 21 as a sole acquired abnormality without GATA1 gene mutation in pediatric acute megakaryoblastic leukemia: a case report and review of the literature.
  • We report a case of pediatric acute megakaryocytic leukemia (AMKL) showing 48,XX,+21,+21 as a sole acquired cytogenetic abnormality without the mutation of GATA1 gene.
  • We could not find any mutations, including known polymorphisms, which are known to be involved in transient myeloproliferative disorder and acute megakaryocytic leukemia of Down syndrome.
  • After achieving complete remission, the tetrasomy 21 disappeared.
  • [MeSH-major] Aneuploidy. Chromosomes, Human, Pair 21. GATA1 Transcription Factor / genetics. Leukemia, Megakaryoblastic, Acute / genetics

  • Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for tetrasomy 21 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18372039.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human
  • [Number-of-references] 31
  •  go-up   go-down


40. Horan JT, Alonzo TA, Lyman GH, Gerbing RB, Lange BJ, Ravindranath Y, Becton D, Smith FO, Woods WG, Children's Oncology Group: Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol; 2008 Dec 10;26(35):5797-801
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group.
  • PURPOSE: There is considerable variation in the use of HLA-matched related bone marrow transplantation (BMT) for the treatment of pediatric patients with newly diagnosed acute myeloid leukemia (AML).
  • Some oncologists have argued that BMT should be offered to most patients in first complete remission (CR).
  • Others have maintained that transplantation in first remission should be reserved for patients with high-risk disease.
  • There were no significant differences for survival in the other two risk groups or in the non-risk-stratified patients.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Jan 1;97(1):56-62 [11133742.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):365-77 [12139720.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):378-84 [12139721.001]
  • [Cites] N Engl J Med. 1996 May 30;334(22):1428-34 [8618581.001]
  • [Cites] Br J Haematol. 1998 Apr;101(1):130-40 [9576193.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2043-53 [16107897.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1044-53 [18000167.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2090-100 [16304571.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2130-8 [16304572.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1315-24 [16254147.001]
  • [Cites] Blood. 2006 Jul 1;108(1):74-80 [16537811.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4499-506 [16983120.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3654-61 [16912228.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2082-9 [16121218.001]
  • (PMID = 18955460.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 98543
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  • [Other-IDs] NLM/ PMC2645105
  •  go-up   go-down


41. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G: Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood; 2006 Feb 1;107(3):880-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
  • To characterize acute megakaryocytic leukemia (FAB M7 AML), we identified 37 patients with M7 AML treated at M.D.
  • Anderson Cancer Center between 1987 and 2003 and compared them with 1800 patients with non-M7, non-M3 AML treated during the same period.
  • The median age of the M7 AML group was 56 years (range, 21-78 years); 22 patients (59%) had an antecedent hematologic disorder or myelodysplastic syndrome or both, and 7 patients (19%) had previously received chemotherapy for other malignancies.
  • Complete remission rates were 43% with M7 AML and 57% with non-M7 AML (P = .089).
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human. Leukemia, Megakaryoblastic, Acute / mortality. Leukemia, Megakaryoblastic, Acute / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16123215.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Kanegane H, Nomura K, Abe A, Makino T, Ishizawa S, Shimizu T, Naoe T, Miyawaki T: Spontaneous regression of aleukemic leukemia cutis harboring a NPM/RARA fusion gene in an infant with cutaneous mastocytosis. Int J Hematol; 2009 Jan;89(1):86-90
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous regression of aleukemic leukemia cutis harboring a NPM/RARA fusion gene in an infant with cutaneous mastocytosis.
  • Aleukemic leukemia cutis has been rarely reported in infant leukemia.
  • This report describes a 6-month-old boy with aleukemic leukemia cutis, which regressed without any treatments within 6 months.
  • Interestingly, a cytogenetic analysis disclosed a leukemia clone with the karyotype of 46, XY, t(5;17)(q35;q12), which generated nucleophosmin (NPM)-retinoic acid receptor alpha fusion (RARA) fusion transcripts.
  • The patient simultaneously had cutaneous mastocytosis, which also disappeared with the leukemia cutis.
  • The present case is partially compatible with systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disorder, proposed by the WHO classification, and it is also suggestive of the initiation or early stage of acute promyelocytic leukemia.
  • [MeSH-major] Leukemia / complications. Mastocytosis, Cutaneous / complications. Oncogene Proteins, Fusion / genetics. Remission, Spontaneous
  • [MeSH-minor] Humans. Infant. Leukemia, Promyelocytic, Acute. Male

  • Genetic Alliance. consumer health - Mast cell disease.
  • Genetic Alliance. consumer health - Cutaneous mastocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19052694.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NPM-RARalpha protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


43. Aimoto M, Yamane T, Inoue A, Momose D, Moriguchi-Aimoto R, Wada-Inoue E, Okamoto S, Koh H, Nakane T, Takeoka Y, Akahori-Nakamae M, Nishiki-Kosaka S, Terada Y, Nakamae H, Koh KR, Nakao T, Ohsawa M, Hino M: [Epstein-Barr virus-associated post-transplant lymphoproliferative disorder diagnosed by the episode of intestinal perforation following allogeneic hematopoietic stem cell transplantation]. Rinsho Ketsueki; 2010 Dec;51(12):1775-80
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epstein-Barr virus-associated post-transplant lymphoproliferative disorder diagnosed by the episode of intestinal perforation following allogeneic hematopoietic stem cell transplantation].
  • A 64-year-old man was diagnosed as having acute myeloid leukemia.
  • We performed sequential treatment with chemotherapy and reduced-intensity stem cell transplantation from an unrelated donor while the patient was in partial remission.
  • After engraftment, he developed acute graft-versus-host disease of the gut on day 42 and steroid therapy was started.
  • On day 159, he complained of acute left lower abdominal pain.
  • Since these cells were positive for CD20 and Epstein-Barr-virus (EBV) encoded RNA, we made a diagnosis of EBV-associated post-transplant lymphoproliferative disorder (PTLD).
  • Reduction in the dose of immunosuppressive agents and rituximab led to complete remission of PTLD.
  • PTLD after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is relatively rare, and the development of gastrointestinal perforation after allo-HSCT is very rare.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Hematopoietic Stem Cell Transplantation / adverse effects. Intestinal Perforation / etiology. Leukemia, Myeloid, Acute / therapy. Lymphoproliferative Disorders / etiology
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived / administration & dosage. Antineoplastic Agents / administration & dosage. Graft vs Host Disease / etiology. Humans. Immunosuppressive Agents / administration & dosage. Male. Middle Aged. Remission Induction. Rituximab. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21258188.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


44. Yoshimi A, Bader P, Matthes-Martin S, Starý J, Sedlacek P, Duffner U, Klingebiel T, Dilloo D, Holter W, Zintl F, Kremens B, Sykora KW, Urban C, Hasle H, Korthof E, Révész T, Fischer A, Nöllke P, Locatelli F, Niemeyer CM, European Working Group of MDS in Childhood (EWOG-MDS): Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia; 2005 Jun;19(6):971-7
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia.
  • Juvenile myelomonocytic leukemia (JMML) is a clonal myeloproliferative disorder of early childhood.
  • In all, 21 patients with JMML who received donor leukocyte infusion (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT) for either mixed chimerism (MC, n=7) or relapse (n=14) were studied.
  • Response rate was significantly higher in patients receiving a higher total T-cell dose (> or =1 x 10(7)/kg) and in patients with an abnormal karyotype.
  • Response was observed in five of six patients who did and in one of 15 children who did not develop acute graft-versus-host disease following DLI (P=0.01).
  • Only one of the responders is alive in remission, two relapsed, and three died of complications.
  • In conclusion, this study shows that some cases of JMML may be sensitive to DLI, this providing evidence for a graft-versus-leukemia effect in JMML.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myelomonocytic, Chronic / therapy. Leukocyte Transfusion

  • Genetic Alliance. consumer health - Juvenile Myelomonocytic Leukemia (JMML).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800672.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


45. Kanno S, Hiura T, Shouji A, Osanai Y, Ujibe M, Ishikawa M: Resistance to Ara-C up-regulates the activation of NF-kappaB, telomerase activity and Fas expression in NALM-6 cells. Biol Pharm Bull; 2007 Nov;30(11):2069-74
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytosine arabinoside (1-beta-D-arabinofuranosylcytosine; Ara-C) is the most important antimetabolite used to induce remission in acute leukemia, but cellular resistance to Ara-C reflects a poor prognosis in cancer chemotherapy.
  • The induction of apoptosis and reduction of cell viability by cytotoxic anti-Fas antibody was more susceptible in resistant cells than parental cells.
  • [MeSH-minor] Antigens, CD95 / metabolism. Apoptosis / drug effects. BH3 Interacting Domain Death Agonist Protein / metabolism. Cell Line, Tumor. Formazans / metabolism. Humans. Leukemia / enzymology. Leukemia / metabolism. Leukemia / pathology. Tetrazolium Salts / metabolism. Tumor Suppressor Protein p53 / metabolism. Up-Regulation / drug effects. bcl-2-Associated X Protein / metabolism

  • Hazardous Substances Data Bank. CYTARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17978477.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antimetabolites, Antineoplastic; 0 / BH3 Interacting Domain Death Agonist Protein; 0 / BID protein, human; 0 / Formazans; 0 / NF-kappa B; 0 / Tetrazolium Salts; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 04079A1RDZ / Cytarabine; 23305-68-2 / MTT formazan; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


46. Seiter K, Liu D, Feldman E, Shi Q, Qureshi A, Arshad M, Walia T, Naseer N, Baskind P, Ahmed T: Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution. Leuk Lymphoma; 2006 Mar;47(3):425-32
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution.
  • Patients with a prior antecedent hematologic disorder were eligible.
  • The overall complete remission rate was 64%, with responses in 78% of patients less than 60 years of age and 51% of patients 60 years of age or older.
  • For a sub-set of patients who would be eligible for most US trials, the complete remission rate was 84% in younger patients and 60% in older patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / drug therapy. Mitoxantrone / therapeutic use
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Cytarabine / administration & dosage. Diagnosis, Differential. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396765.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


47. Keating GM: Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia. Drugs; 2009;69(17):2501-18
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.
  • Subcutaneous azacitidine was recently approved in the EU for the treatment of adults who are not eligible for haematopoietic stem cell transplantation and who have intermediate-2-risk or high-risk myelodysplastic syndromes (MDS) [according to International Prognostic Scoring System (IPSS) criteria], chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder, or acute myeloid leukaemia (AML) with 20-30% blasts and multilineage dysplasia (according to the WHO classification).
  • In addition, azacitidine is associated with a lower risk of AML progression and higher rates of complete remission, partial remission, haematological improvement and red blood cell (RBC) transfusion independence.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Azacitidine / therapeutic use. Combined Modality Therapy. Leukemia, Myeloid, Acute / drug therapy. Prognosis. Risk Assessment
  • [MeSH-minor] Bone Marrow / drug effects. Bone Marrow Cells. Chromosome Inversion. Erythrocyte Transfusion. Erythroid Precursor Cells. Hematopoietic Stem Cell Transplantation / adverse effects. Humans. Myelodysplastic Syndromes. Randomized Controlled Trials as Topic. Remission Induction. Stem Cell Transplantation / adverse effects. Transplantation Conditioning / mortality. Treatment Outcome


48. Lofstad GE, Reinfjell T, Hestad K, Diseth TH: Cognitive outcome in children and adolescents treated for acute lymphoblastic leukaemia with chemotherapy only. Acta Paediatr; 2009 Jan;98(1):180-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cognitive outcome in children and adolescents treated for acute lymphoblastic leukaemia with chemotherapy only.
  • OBJECTIVE: To examine cognitive outcome in children and adolescents with acute lymphoblastic leukaemia (ALL) in remission, treated with central nervous system prophylactic chemotherapy only.
  • METHOD: Thirty-five children and adolescents, age 8.4-15.3 years in long-term remission from ALL, 4.2-12.4 years post diagnosis, without relapse and no pre-diagnosis history of neurodevelopmental disorder were compared with 35 healthy controls matched for gender and age, on measures of intellectual functioning Wechsler Intelligence Scale for Children-Third Edition (WISC-III).
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cognition / drug effects. Cognition Disorders / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ment Retard Dev Disabil Res Rev. 2006;12(3):174-83 [17061283.001]
  • [Cites] J Pediatr Psychol. 2000 Mar;25(2):59-68 [10820944.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2267-75 [11187918.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Feb;24(2):106-14 [11990695.001]
  • [Cites] Dev Neuropsychol. 2002;21(2):173-95 [12139198.001]
  • [Cites] Eur J Cancer. 2003 Feb;39(3):359-65 [12565989.001]
  • [Cites] Child Neuropsychol. 2004 Mar;10(1):14-23 [14977512.001]
  • [Cites] J Clin Exp Neuropsychol. 2004 Aug;26(5):684-97 [15370390.001]
  • [Cites] J Child Psychol Psychiatry. 1988 Nov;29(6):839-52 [3069852.001]
  • [Cites] Arch Dis Child. 1995 Aug;73(2):136-40 [7574857.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2490-6 [7595698.001]
  • [Cites] J Dev Behav Pediatr. 1996 Dec;17(6):392-8 [8960568.001]
  • [Cites] J Pediatr Psychol. 1997 Dec;22(6):861-70 [9494322.001]
  • [Cites] J Pediatr Psychol. 1998 Oct;23(5):333-40 [9782681.001]
  • [Cites] Arch Neurol. 1998 Dec;55(12):1561-8 [9865801.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2608-17 [9874469.001]
  • [Cites] Pediatr Blood Cancer. 2005 May;44(5):478-86 [15918215.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Neuropsychology. 2000 Apr;14(2):189-200 [10791859.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):941-9 [16411228.001]
  • (PMID = 18826490.001).
  • [ISSN] 1651-2227
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2659382
  •  go-up   go-down


49. Lee J, Kern WF, Cain JB, Mulvihill JJ, Li S: A variant t(8;10;21) in a patient with pathological features mimicking atypical chronic myeloid leukemia. Cancer Genet Cytogenet; 2005 May;159(1):79-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A variant t(8;10;21) in a patient with pathological features mimicking atypical chronic myeloid leukemia.
  • We report the case of an 11-year-old girl who was initially diagnosed with a chronic myeloproliferative disorder, possibly chronic myelogenous leukemia (CML), based on laboratory and blood and marrow morphological findings.
  • The treatment regime was switched to an acute myeloid leukemia (AML) protocol; the patient responded well and is now in remission.
  • This case demonstrates again that routine clinical cytogenetic analysis plays an important role in the clinical diagnosis, guidance of treatment, and prognostication in hematological disorders.
  • [MeSH-major] Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 21 / genetics. Chromosomes, Human, Pair 8 / genetics. Genetic Variation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Translocation, Genetic


50. Ravandi F, Cortes J, Faderl S, O'Brien S, Garcia-Manero G, Verstovsek S, Santos FP, Shan J, Brandt M, de Lima M, Pierce S, Kantarjian H: Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood; 2010 Dec 23;116(26):5818-23; quiz 6153
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.
  • Refractory patients were older (median age, 59 vs 56 years; P < .001), more likely with unfavorable cytogenetics (P < .001) and antecedent hematologic disorder (P < .001), and had a higher presentation white blood cell count (P = .04), but not a higher incidence of FLT3 mutations (P = .85), than those achieving CR.
  • Nineteen patients (7%) were alive and in CR for at least 6 months, including 9 who underwent allogeneic stem cell transplantation.
  • On multivariate analysis, severe thrombocytopenia, leukocytosis, increasing marrow blast percentage, unfavorable cytogenetics, and salvage not including allogeneic stem cell transplantation were associated with a worse survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anthracyclines / administration & dosage. Cytarabine / administration & dosage. Female. Humans. Male. Middle Aged. Remission Induction. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1235-48 [19776405.001]
  • [Cites] Curr Opin Hematol. 2009 Mar;16(2):98-104 [19468271.001]
  • [Cites] J Clin Oncol. 2010 Apr 1;28(10):1766-71 [20159819.001]
  • [Cites] Cancer. 2010 Nov 1;116(21):5012-21 [20629023.001]
  • [Cites] Leukemia. 2000 Mar;14(3):476-9 [10720145.001]
  • [Cites] Blood. 2002 Jul 1;100(1):59-66 [12070009.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3097-9 [12842982.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Haematologica. 2004 Aug;89(8):998-1008 [15339685.001]
  • [Cites] Leukemia. 1998 Jul;12(7):1049-55 [9665189.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):69-79 [10520026.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1969-78 [15632409.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):116-24 [16721819.001]
  • [Cites] Cancer. 2007 Nov 1;110(9):1900-10 [17786921.001]
  • [Cites] Haematologica. 2008 Aug;93(8):1263-5 [18519513.001]
  • [Cites] Curr Opin Hematol. 2009 Mar;16(2):64-9 [19468266.001]
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1249-59 [19776406.001]
  • (PMID = 20923968.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 04079A1RDZ / Cytarabine
  • [Other-IDs] NLM/ PMC4081278
  •  go-up   go-down


51. Stańczak E, Pawelec K, Romiszewski M: [Lymphoproliferative disorder as a complication after haematopoietic stem cell transplantation]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1117-21
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphoproliferative disorder as a complication after haematopoietic stem cell transplantation].
  • Lymphoproliferative disorders (LPD) occur often in EBV-infected patients, especially in solid-organ and haematopoietic stem cell transplant recipients.
  • The risk of developing LPD ranges from 1 to 25% and depends on the type of transplantation.
  • We are presenting the case of a 9-year-old boy with acute myelogenous leukaemia in second remission, who developed LPD after matched unrelated donor bone marrow transplantation (MUD BMT) not identical in two loci.
  • Bone marrow biopsy confirmed continuing remission.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Lymphoproliferative Disorders / etiology
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Child. Fatal Outcome. Fibrinolytic Agents / therapeutic use. Humans. Immunologic Factors / therapeutic use. Leukemia, Myeloid, Acute / therapy. Male. Polydeoxyribonucleotides / therapeutic use. Pulmonary Edema / etiology. Rituximab

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531835.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Fibrinolytic Agents; 0 / Immunologic Factors; 0 / Polydeoxyribonucleotides; 438HCF2X0M / defibrotide; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


52. Staal-Viliare A, Latger-Cannard V, Rault JP, Didion J, Grégoire MJ, Bologna S, Witz B, Jonveaux P, Lecompte T, Rio Y: [A case of de novo acute basophilic leukaemia: diagnostic criteria and review of the literature]. Ann Biol Clin (Paris); 2006 Jul-Aug;64(4):361-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of de novo acute basophilic leukaemia: diagnostic criteria and review of the literature].
  • [Transliterated title] A propos d'un cas de leucémie à basophiles de novo: critères diagnostiques et revue de la littérature.
  • We report a case of a de novo acute basophilic leukaemia, revealed by an infectious pneumopathy in a 73 year old man.
  • Thus, imatinib was added to the conventional chimiotherapy and the patient is currently in complete remission.
  • This clinical prompted allows us to review the literature on acute basophilic leukaemia and to state on the different diagnostic criteria of this rare disorder.
  • [MeSH-major] Leukemia, Basophilic, Acute / blood. Leukemia, Basophilic, Acute / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16829481.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


53. Edlin R, Connock M, Tubeuf S, Round J, Fry-Smith A, Hyde C, Greenheld W: Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia. Health Technol Assess; 2010 May;14 Suppl 1:69-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
  • This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of azacitidine (aza) compared with conventional care regimes (CCR) for higher risk patients with myelodysplastic syndrome (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML), based on the evidence submission from the manufacturer to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process.
  • The results showed that: the median overall survival was 24.5 months on aza, compared with 15.0 months in the CCR group (p = 0.0001); the response rates were low (complete remission 17% aza versus 8% CCR); the median time to transformation to AML was greater in the aza group (17.8 versus 11.5 months; p < 0.0001); and of patients who were red blood cell (RBC) transfusion-dependent at baseline, 45% of those on aza became RBC transfusion-independent during the treatment period, compared with 11.8% in the CCR group (p < 0.0001).
  • At the time of writing, the guidance appraisal consultation document issued by NICE on 4 March 2010 states that azacitidine is not recommended as a treatment option for people not eligible for haemopoietic stem cell transplantation with the the following conditions: intermediate-2 and high-risk MDS according to the International Prognostic Scoring System, CMML with 10-29% marrow blasts without myeloproliferative disorder, or with AML with 20-30% blasts and multilineage dysplasia, according to World Health Organization classification.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Azacitidine / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myelomonocytic, Chronic / drug therapy. Myelodysplastic Syndromes / drug therapy


54. Zhang LJ, Shin ES, Yu ZX, Li SB: Molecular genetic evidence of Y chromosome loss in male patients with hematological disorders. Chin Med J (Engl); 2007 Nov 20;120(22):2002-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These patients were divided into two groups: the study group, including 237 patients who had hematological disorders included myeloproliferative disorder (MPD), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), multiple myeloma (MM), and lymphoma and the control group including 355 patients with no evidence of hematological disease.
  • Two of the patients, one with AML and another with CML, had karyotype and FISH testing done both at the initial diagnosis and during remission.
  • The results showed a loss of Y chromosome at initial diagnosis but a normal 46, XY karyotype during remission.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. In Situ Hybridization, Fluorescence. Leukemia / genetics. Lymphoma / genetics. Male. Middle Aged. Myelodysplastic Syndromes / genetics. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067786.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


55. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G: Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A; 2010 Apr 20;107(16):7473-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A phase II clinical trial with single-agent decitabine was conducted in older patients (>or=60 years) with previously untreated acute myeloid leukemia (AML) who were not candidates for or who refused intensive chemotherapy.
  • Nineteen (36%) had antecedent hematologic disorder or therapy-related AML; 16 had complex karyotypes (>or=3 abnormalities).
  • The complete remission rate was 47% (n = 25), achieved after a median of three cycles of therapy.
  • Complete remission was achieved in 52% of subjects presenting with normal karyotype and in 50% of those with complex karyotypes.
  • [MeSH-major] Azacitidine / analogs & derivatives. Leukemia, Myeloid, Acute / metabolism. MicroRNAs / biosynthesis
  • [MeSH-minor] Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Cohort Studies. DNA Methylation. Disease-Free Survival. Female. Humans. Karyotyping. Male. Middle Aged. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2009 Jun;145(5):598-605 [19344426.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2867-8 [19299654.001]
  • [Cites] Blood. 2009 Aug 6;114(6):1166-73 [19470696.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3842-8 [19528372.001]
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1235-48 [19776405.001]
  • [Cites] Br J Haematol. 2010 Jan;148(1):48-58 [19821823.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):556-61 [20026803.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):562-9 [20026804.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):549-55 [20026805.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2429-40 [12011120.001]
  • [Cites] Leukemia. 2003 Feb;17(2):350-8 [12592335.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1635-40 [14604977.001]
  • [Cites] Blood. 1987 Aug;70(2):412-7 [3607279.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):103-7 [9916800.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1277-84 [15735013.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1794-803 [16532500.001]
  • [Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6361-9 [16778214.001]
  • [Cites] Blood. 2006 Jul 1;108(1):63-73 [16522815.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3271-9 [16882711.001]
  • [Cites] Blood. 2007 Jan 1;109(1):52-7 [16882708.001]
  • [Cites] Br J Haematol. 2007 Feb;136(4):624-7 [17223919.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1114-24 [17315155.001]
  • [Cites] Blood. 2007 Aug 1;110(3):1080-2; author reply 1083 [17644749.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3884-91 [17679729.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15805-10 [17890317.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1638-45 [18565853.001]
  • [Cites] Lancet Oncol. 2009 Mar;10(3):223-32 [19230772.001]
  • [Cites] Blood. 2009 Jun 18;113(25):6411-8 [19211935.001]
  • (PMID = 20368434.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00492401
  • [Grant] United States / NCI NIH HHS / CA / P50 CA140158; United States / NCI NIH HHS / CA / R01 CA102031; United States / NCI NIH HHS / CA / K23 CA120708; United States / NCI NIH HHS / CA / K12CA133250; United States / NCI NIH HHS / CA / K23CA120708; United States / NCI NIH HHS / CA / K12 CA133250; United States / NCI NIH HHS / CA / N01CM62207; United States / NCI NIH HHS / CM / N01-CM-62207
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / MIRN29 microRNA, human; 0 / MicroRNAs; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC2867720
  •  go-up   go-down


56. Rudd E, Göransdotter Ericson K, Zheng C, Uysal Z, Ozkan A, Gürgey A, Fadeel B, Nordenskjöld M, Henter JI: Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies. J Med Genet; 2006 Apr;43(4):e14
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the frequency and spectrum of mutations in the gene encoding syntaxin 11 (STX11) in familial haemophagocytic lymphohistiocytosis (FHL), a rare autosomal recessive disorder of immune dysregulation characterised by a defect in natural killer cell function.
  • Three patients experienced long periods (> or = 1 year) in remission without specific treatment, which is very uncommon in this disease.
  • Two of the six patients harbouring STX11 gene defects developed myelodysplastic syndrome (MDS) or acute myelogenous leukaemia (AML).
  • [MeSH-major] Leukemia, Myeloid / genetics. Lymphohistiocytosis, Hemophagocytic / diagnosis. Lymphohistiocytosis, Hemophagocytic / genetics. Mutation. Myelodysplastic Syndromes / genetics. Qa-SNARE Proteins / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged, 80 and over. Child. Child, Preschool. DNA Mutational Analysis. Female. Genotype. Humans. Infant. Male. Pedigree. Phenotype. Psychomotor Disorders / complications. Psychomotor Disorders / genetics. Remission, Spontaneous


57. Jones CM, Dickinson TM, Salvado A: Phase II open label trial of imatinib in polycythemia rubra vera. Int J Hematol; 2008 Dec;88(5):489-94
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Polycythemia rubra vera is a chronic myeloproliferative disorder characterized by panmyelosis with the resultant potential for thrombosis, myelofibrosis, and acute leukemia.
  • These patients have remained in complete hematologic remission on imatinib since 1999.
  • Patients meeting the Polycythemia Vera Study group criteria for the diagnosis of polycythemia vera, either naïve or intolerant to prior treatment were allowed to enroll.
  • Twenty patients were enrolled, 15 achieved complete hematologic remission within 12 weeks and ten remain on study.
  • Six patients remain in remission on 400 mg a day and four on 500 mg a day.
  • Imatinib mesylate is capable of producing hematologic remission in the majority of patients with polycythemia vera and provides another option for patient management, particularly in those intolerant to hydroxyurea.
  • [MeSH-minor] Adult. Aged. Benzamides. Dose-Response Relationship, Drug. Female. Gastrointestinal Diseases / blood. Gastrointestinal Diseases / chemically induced. Hematocrit. Humans. Imatinib Mesylate. Male. Middle Aged. Platelet Count. Remission Induction. Skin Diseases / blood. Skin Diseases / chemically induced

  • Genetic Alliance. consumer health - Polycythemia vera.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19009241.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


58. Schaffer JV, McNiff JM, Seropian S, Cooper DL, Bolognia JL: Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: expanding the sclerodermoid spectrum. J Am Acad Dermatol; 2005 Oct;53(4):591-601
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eosinophilic fasciitis (EF) (a fibrosing disorder related to deep morphea) and lichen sclerosus (LS) have also been reported as manifestations of sclerodermoid GVHD.
  • EF involved the extremities (sparing the hands and feet), and was characterized clinically by an acute onset of pain and edema followed by induration with a rippled appearance.
  • [MeSH-minor] Adult. Chronic Disease. Female. Humans. Leukemia, Myeloid, Acute / surgery. Lymphoma, Large B-Cell, Diffuse / surgery. Magnetic Resonance Imaging. Male. Middle Aged. Remission Induction. Stem Cell Transplantation


59. Gelsi-Boyer V, Vey N: [Recent advances in the treatment of myelodysplastic syndromes]. Rev Med Interne; 2006 Aug;27(8):600-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Avancées dans la prise en charge des syndromes myélodysplasiques.
  • OBJECTIVES: Myelodysplastic syndromes (MDS) are a group of clonal hematologic disorder, which combine ineffective hematopoiesis and evolution to acute myeloid leukemia.
  • There is currently no standard treatment for MDS and allogeneic stem cell transplantation remains the only curative strategy.

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16713027.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Immunosuppressive Agents
  • [Number-of-references] 57
  •  go-up   go-down


60. Ostgård LS, Kjeldsen E, Holm MS, Brown Pde N, Pedersen BB, Bendix K, Johansen P, Kristensen JS, Nørgaard JM: Reasons for treating secondary AML as de novo AML. Eur J Haematol; 2010 Sep;85(3):217-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reasons for treating secondary AML as de novo AML.
  • In a Danish bi-regional registry-based study, we conducted an analysis of the incidence and clinical importance of secondary acute myeloid leukaemia (AML).
  • The secondary leukaemia arose from MDS (myelodysplastic syndrome) in 77 cases (49%), CMPD (chronic myeloproliferative disorder) in 43 cases (27%) and was therapy-related AML (t-AML) in 37 cases (24%).
  • Median age at diagnosis of AML was 69 yr in secondary cases when compared to 66 yr in de novo cases (P = 0.006).
  • In univariate analyses, secondary AML was associated with an inferior complete remission (CR) rate (P = 0.008) and poorer overall survival (OS, P = 0.003) whereas in complete remitters, disease-free survival (DFS) of secondary cases was equal to that of de novo cases.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / complications


61. Chen X, Zhang Y, Li Y, Lei P, Zhai Y, Liu L: Biphenotypic hematologic malignancy: a case report of the 8p11 myeloproliferative syndrome in a child. J Pediatr Hematol Oncol; 2010 Aug;32(6):501-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY: The 8p11 myeloproliferative syndrome, also known as stem cell leukemia/lymphoma, is a rare, atypical, myeloproliferative disorder and lymphoid malignancy associated with chromosomal abnormalities involving the 8p11 chromosomal band.
  • Disease phenotypes associated with this translocation include poor prognosis and transformation to acute leukemia and non-Hodgkin lymphoma.
  • In common with a T-cell phenotype, obtaining and maintaining remission is difficult by conventional chemotherapy.
  • This study describes an illustrative case of 8p11 myeloproliferative syndrome/stem cell leukemia/lymphoma outlining its chief features and historical developments.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Humans. Male. Phenotype. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Prednisone / therapeutic use. Syndrome. Translocation, Genetic. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20562652.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CVAD protocol; EPOCH protocol
  •  go-up   go-down


62. Chang HH, Lu MY, Jou ST, Lin KH, Tien HF, Wu ET, Lin DT: Neoplastic disorders of hematopoiesis in children with Down's syndrome--a single institution experience in Taiwan. J Formos Med Assoc; 2005 May;104(5):333-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: All DS patients aged < 18 years of age with a diagnosis of leukemia or myelodysplastic syndrome (MDS) from 1990 to 2002 were included in this retrospective study.
  • The clinical and laboratory characteristics of patients, including age at diagnosis, gender, initial hemogram, cytogenetic findings, immunophenotype, treatment regimen and outcomes were analyzed.
  • Among them, 9 patients (56%) had acute myeloid leukemia (AML), mainly of the megakaryoblastic subtype.
  • Of the 5 patients who underwent chemotherapy, 3 remained in remission with a survival time of 29, 59, and 109 months, and the remaining 2 died as a consequence of chemotherapy toxicity.
  • Among the 6 patients (38%) who developed transient myeloproliferative disorder, 2 were lost to follow-up, 2 died from DS-associated congenital heart abnormalities and 2 survived without any AML changes.
  • The remaining 1 patient (6%) who developed ALL was still in his first remission although this patient suffered profound chemotherapy complications during treatment.
  • CONCLUSIONS: This study found that AML is the most common hematologic neoplasm in Taiwanese children with DS, especially megakaryoblastic leukemia.
  • Long-term remission of AML in DS patients can be achieved with appropriate treatment.

  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15959600.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


63. Vasudev B, Hariharan S: Cancer after renal transplantation. Curr Opin Nephrol Hypertens; 2007 Nov;16(6):523-8
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Prolonged waiting times for renal transplantation, an increase in the average age of recipients, decreased acute rejection rates due to use of newer potent immunosuppressives and improving long-term transplant survival have raised concerns in the transplant community regarding posttransplant cancer.
  • RECENT FINDINGS: Recent evidence indicates that sirolimus is associated with a decreased incidence of posttransplant de-novo cancer and remission of Kaposi's sarcoma and nonmelanoma skin cancer.
  • Mycophenolate mofetil has been shown to have an antiproliferative activity against leukemia and lymphoma and an anti-tumor effect against colon and prostate cancer.
  • Clinically it has been shown to be associated with a reduced incidence of cancers like posttransplant lymphoproliferative disorder.

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089965.001).
  • [ISSN] 1062-4821
  • [Journal-full-title] Current opinion in nephrology and hypertension
  • [ISO-abbreviation] Curr. Opin. Nephrol. Hypertens.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid; W36ZG6FT64 / Sirolimus
  • [Number-of-references] 63
  •  go-up   go-down


64. Creamer D, Martyn-Simmons CL, Osborne G, Kenyon M, Salisbury JR, Devereux S, Pagliuca A, Ho AY, Mufti GJ, du Vivier AW: Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy. Arch Dermatol; 2007 Sep;143(9):1157-62
Hazardous Substances Data Bank. PSORALEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Within a large population of individuals who underwent allogeneic stem cell transplantation because of hematologic malignancy, a group of patients was identified in whom severe and persistent eczema developed.
  • OBSERVATIONS: We prospectively evaluated 10 adult patients with unexplained eczematous dermatosis after allogeneic hematopoietic stem cell transplantation.
  • The patient group had strong risk factors for chronic cutaneous GVHD: 8 had received a transplant from an unrelated donor, 7 had evidence of extracutaneous GVHD, and 7 had a history of acute cutaneous GVHD.
  • Four patients achieved prolonged remission.
  • Six patients died, 5 of infective complications and 1 of relapsed leukemia.
  • Although atopy can be transmitted to an individual from a hematopoietic stem cell transplant, none of the donors in this series gave a history of an atopic disorder.
  • [MeSH-major] Eczema / pathology. Ficusin / therapeutic use. Graft vs Host Disease / pathology. Hematopoietic Stem Cell Transplantation / adverse effects. PUVA Therapy. Photosensitizing Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Eczema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2008 Aug;144(8):1066; author reply 1066-7 [18711091.001]
  • (PMID = 17875877.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; KTZ7ZCN2EX / Ficusin
  •  go-up   go-down


65. Meister B, Zelger B, Kropshofer G, Klein-Franke A, Crazzolara R, Frühwirth M, Neu N: Extracorporeal membrane oxygenation as a rescue therapy for leukaemic children with pulmonary failure. Br J Haematol; 2010 Jan;148(1):126-31
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In patients with leukaemia, acute respiratory distress syndrome (ARDS) secondary to intensified chemotherapy-induced immunosuppression is a devastating disorder resulting in high morbidity and mortality.
  • We describe the use of ECMO in four children with ARDS and leukaemia.
  • Two patients (50%) survived, pulmonary function recovered and they are in prolonged first remission.
  • All patients had a highly increased demand for packed platelet and red blood cell transfusions.
  • We concluded that ECMO is a supportive tool to reduce the incidence of early death, treatment-related mortality and, ultimately, to improve overall survival in childhood leukaemia.
  • [MeSH-major] Extracorporeal Membrane Oxygenation. Leukemia / complications. Respiratory Distress Syndrome, Adult / therapy

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19821829.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


66. Pasmant E, Ballerini P, Lapillonne H, Perot C, Vidaud D, Leverger G, Landman-Parker J: SPRED1 disorder and predisposition to leukemia in children. Blood; 2009 Jul 30;114(5):1131
MedlinePlus Health Information. consumer health - Congenital Heart Defects.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SPRED1 disorder and predisposition to leukemia in children.
  • [MeSH-major] Genes, ras. Heart Defects, Congenital / genetics. Intracellular Signaling Peptides and Proteins / deficiency. Leukemia, Monocytic, Acute / genetics. Membrane Proteins / deficiency. Neurocutaneous Syndromes / genetics
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendicitis / complications. Cell Transformation, Neoplastic / genetics. Genetic Predisposition to Disease. Humans. Infant. MAP Kinase Signaling System. Male. Pseudomonas Infections / complications. Remission Induction. Sepsis / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2010 Mar 25;115(12):2557-8 [20339110.001]
  • (PMID = 19643996.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / SPRED1 protein, human
  •  go-up   go-down






Advertisement